B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eton Pharmaceuticals, Inc. - Common Stock (NQ: ETON )

13.05 -0.52 (-3.83%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 98,708
Open 13.48
Bid (Size) 13.05 (3)
Ask (Size) 13.08 (180)
Prev. Close 13.57
Today's Range 12.80 - 13.69
52wk Range 3.030 - 13.98
Shares Outstanding 25,688,062
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial
Clinical Trial Demonstrates Clinical and Statistical Improvement in Metabolic Control During Prolonged Fasting in PKU Patients - Results Expected to Promote Awareness and Adoption of PKU GOLIKE® 
From Eton Pharmaceuticals
Via GlobeNewswire

Performance

YTD
+184.31%
+184.31%
1 Month
+2.43%
+2.43%
3 Month
+125.00%
+125.00%
6 Month
+296.66%
+296.66%
1 Year
+183.70%
+183.70%

More News

Read More
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)
From Eton Pharmaceuticals
Via GlobeNewswire
Analyst Expectations For Eton Pharmaceuticals's Future
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Earnings Outlook For Eton Pharmaceuticals
Via Benzinga
Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Awarded Second Patent for ET-400 (Hydrocortisone Oral Solution)
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
From Eton Pharmaceuticals
Via GlobeNewswire
Critical Insights From Eton Pharmaceuticals Analyst Ratings: What You Need To Know
Via Benzinga
SWK Holdings Provides Portfolio Update
Via ACCESSWIRE
3 Stocks Insiders Are Buying Heavily In October 2024, And Why
Via Talk Markets
Domino's Pizza To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
From Eton Pharmaceuticals
Via GlobeNewswire
ETON Stock Earnings: Eton Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
From Eton Pharmaceuticals
Via GlobeNewswire
SWK Holdings Highlights Recent Achievements and Provides Portfolio Update
Via ACCESSWIRE
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
From Eton Pharmaceuticals
Via GlobeNewswire
ETON Stock Earnings: Eton Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Eton Pharmaceuticals Reports First Quarter 2024 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
From Eton Pharmaceuticals
Via GlobeNewswire
Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
From Eton Pharmaceuticals
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.